Scalable AAV Manufacturing: Addressing Challenges Across the Workflow
Broadcast Date: February 2, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Whether it’s a vector for the latest gene therapy breakthrough or the delivery of a pandemic vaccine, adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method. AAV has an efficacy and safety profile that makes it an ideal therapeutic vector—already part of several high-profile drug approvals in both the US and Europe. Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral manufacturing pipelines deliver a consistent, pure, and high-titer product that exhibits good safety and efficacy in order to meet regulatory requirements.
In this GEN webinar, our presenters will highlight upstream and downstream solutions across the AAV production workflows. Specifically, we will learn about scalable, high-titer AAV production in two cell host systems: a helper free 293F-based suspension system and the insect-cell based ExpiSf™ Expression System. Additionally, we will hear about the benefits of utilizing a specifically engineered affinity chromatography resin in the downstream purification of AAV, which can significantly improve viral clearance. Finally, our panel will focus on the regulatory requirements for safety and purity testing during the AAV production process, as well as discuss the benefits of implementing automated systems to save time and demonstrate product quality and safety.
A Q&A session followED the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: